Organization of biological therapy for patients with severe eosinophilic bronchial asthma in the Krasnoyarsk region

Patients with severe bronchial asthma, which remains uncontrolled despite the optimal basic therapy, carry a significant healthcare burden and require substantial financial investments. Severe asthma is a heterogeneous airway disease with complex pathophysiological mechanisms that can be broadly divided into inflammatory pathways with eosinophilic and non-eosinophilic inflammation.

Aim. This study aimed to analyze the literature data on the use of targeted genetic engineering therapy in patients with severe bronchial asthma, as well as to analyze the organization of immunobiological therapy in the Krasnoyarsk Territory. The addition of targeted drugs for severe eosinophilic bronchial asthma based on phenotyping has proven to be effective and is recommended by all current guidelines. Today, several biologics targeting specific endotypes and phenotypes has been approved for the treatment of severe eosinophilic asthma worldwide. These are antibodies binding immunoglobulin E (omalizumab), antagonists of interleukin-5 (mepolizumab, reslizumab) and its receptor (benralizumab), as well as antibodies selectively binding to the IL-4 and IL-13 receptors (dupilumab). Eosinophilic inflammation therapy is a relatively new direction of asthma treatment, and understanding its long-term efficacy and safety is important.

Conclusion. It is essential to differentiate patients with severe eosinophilic asthma from the general cohort of asthma patients, timely refer them to specialists who can prescribe this therapy and have experience with it, select the drug correctly, and monitor the patients during the treatment. This article describes organization of biological therapy for patients with severe eosinophilic bronchial asthma in the Krasnoyarsk Territory.

1. FitzGerald J.M., Bleecker E.R., Nair P. et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016; 388: 2128–2141. DOI: 10.1016/S0140-6736(16)31322-8.

2. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma. 2022. Available at: https://ginasthma.org/gina-reports/

3. Nenasheva N.M. [Severe eosinophilic bronchial asthma: new therapeutic options]. Meditsinskiy sovet. 2018; (15): 44–52 DOI: 10.21518/2079-701X-2018-15-44-52 (in Russian).

4. Bleecker E.R., FitzGerald J.M., Chanez P. et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10056): 2115–2127. DOI: 10.1016/S0140-6736(16)31324-1.

5. Nedogoda S.V., Salasyuk A.S., Barykina I.N. et al. [Cost of the biological therapy for severe bronchial asthma treatment at inpatient and day care setting]. Meditsinskie tekhnologii. 2020; 39 (1): 61–69. Available at: https://www.mediasphera.ru/issues/meditsinskie-tekhnologii-otsenka-i-vybor/2020/1/ (in Russian).

6. Buhl R., Humbert M., Bjermer L. et al. Severe eosinophilic asthma: a roadmap to consensus. Eur. Respir. J. 2017; 49 (5): 1700634. DOI: 10.1183/13993003.00634-2017.

7. Demko I.V., Sobko E.A., Chubarova S.V. et al. [Features of the systemic inflammation, external respiration functions and morphological structure of the bronchial mucous membrane in severe bronchial asthma]. Sibirskoe meditsinskoe obozrenie. 2014; (5): 47–52. Available at: https://smr.krasgmu.ru/journal/1262_47-52.pdf (in Russian).

8. Ragnoli B., Morjaria J., Pignatti P. et al. Dupilumab and tezepelumab in severe refractory asthma: new opportunities. Ther. Adv. Chronic Dis. 2022; 25 (13): 20406223221097327. DOI: 10.1177/20406223221097327.

9. Nenasheva N.M. [Т2-high and T2-low bronchial asthma, endotype characteristics and biomarkers]. Pul’monologiya. 2019; 29 (2): 216–228. DOI: 10.18093/0869-0189-2019-29-2-216-228 (in Russian).

10. Schleich F.N., Chevremont A., Paulus V. et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur. Respir. J. 2014; 44 (1): 97–108. DOI: 10.1183/09031936.00201813.

11. Jackson D.J., Korn S., Mathur S.K. et al. Safety of eosinophil-depleting therapy for severe, eosinophilic asthma: focus on benralizumab. Drug Saf. 2020; 43 (5): 409–425. DOI: 10.1007/s40264020-00926-3.

12. Nenasheva N.M., Kurbacheva O.M., Avdeev S.N. et al. [Practical recommendations for choosing an immunobiological preparation for the treatment of severe bronchial asthma of T2-endotype]. Pul’monologiya. 2020; 30 (2): 227–244. DOI: 10.18093/0869-0189-2020-30-2-227-244 (in Russian).

13. Castro M., Corren J., Pavord I.D. et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N. Engl. J. Med. 2018; 378 (26): 2486–2496. DOI: 10.1056/NEJMoa1804092.

14. Bachert C., Han J.K., Desrosiers M. et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019; 394 (10209): 1638–1650. DOI: 10.1016/S0140-6736(19)31881-1.

15. Jackson D.J., Korn S., Mathur S.K. et al. Safety of eosinophil-depleting therapy for severe, eosinophilic asthma: focus on benralizumab. Drug Saf. 2020; 43 (5): 409–425. DOI: 10.1007/s40264-020-00926-3.

16. Mizernitskiy Yu.L., Mel’nikova I.M., Pavlenko V.A. [Mepolizumab in the treatment of bronchial asthma in children]. Meditsinskiy sovet. 2020; (1): 81–86. DOI: 10.21518/2079-701X-2020-1-81-86 (in Russian).

17. Ortega H.G., Liu M.C., Pavord I.D. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 2014; 371 (13): 1198–1207. DOI: 10.1056/NEJMoa1403290.

18. Bel E.H., Wenzel S.E., Thompson P.J. et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N. Engl. J. Med. 2014; 371: 1189–1197. DOI: 10.1056/NEJMoa1403291.

19. Albers F.C., Price R.G., Smith S.G., Yancey S.W. Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. J. Allergy Clin. Immunol. 2017; 140 (5): 1464–1466.e4. DOI: 10.1016/j.jaci.2017.06.010.

20. Egan R.W., Athwal D., Bodmer M.W. et al. Effect of Sch 55700, a humanized monoclonal antibody to human in-terleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung. 1999; 49 (9): 779–790. DOI: 10.1055/s-0031-1300502.

21. Castro M., Zangrilli J., Wechsler M.E. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, doubleblind, randomised, placebocontrolled, phase 3 trials. Lancet Respir. Med. 2015; 3 (5): 355–366. DOI: 10.1016/s2213-2600(15)00042-9.

22. Mukherjee M., Paramo F.A., Kjarsgaard M. et al. Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab. Am. J. Respir. Crit. Care Med. 2018; 197 (1): 38–46. DOI: 10.1164/rccm.201707-1323OC.

23. Harrison T.W., Chanez P., Menzella F.et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir. Med. 2021; 9 (3): 260–274. DOI: 10.1016/s2213-2600(20)30414-8.

24. Menzies-Gow A., Corren J., Bourdin A. et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N. Engl. J. Med. 2021; 384 (19): 1800–1809. DOI: 10.1056/NEJMoa2034975.

25. Ortega H.G., Yancey S.W., Mayer B. et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir. Med. 2016; 4 (7): 549–556. DOI: 10.1016/S2213-2600(16)30031-5.

26. Castro M., Corren J., Pavord I.D. et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N. Engl. J. Med. 2018; 378 (26): 2486–2496. DOI: 10.1056/NEJMoa1804092.

27. FitzGerald J.M., Bleecker E.R., Menzies-Gow A. et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir. Med. 2018; 6 (1): 51–64. DOI: 10.1016/S22132600(17)30344-2.

28. Nowak R.M., Parker J.M., Silverman R.A. et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma. Am. J. Emerg. Med. 2015; 33 (1): 14–20. DOI: 10.1016/j.ajem.2014.09.036.

29. Nolasco S., Campisi R., Intravaia R. et al. Case report: Acute effect of benralizumab on asthma exacerbation without concomitant corticosteroid use. F1000Res. 2020; 9: 637. DOI: 10.12688/f1000research.24603.2.

30. Mogensen I., Alving K., Dahlen S.E. et al Fixed airflow obstruction relates to eosinophil activation in asthmatics. Clin. Exp. Allergy. 2019; 49 (2): 155–162. DOI: 10.1111/cea.13302.

31. Agache I., Akdis C.A., Akdis M. et al. EAACI biologicals guidelines-recommendations for severe asthma. Allergy. 2021; 76 (1): 14–44. DOI: 10.1111/all.14425.